Understanding Breast Cancer

Breast cancer starts when cells in the breast grow abnormally and become malignant. In India, over 178,000 women are diagnosed with breast cancer each year, making it the most common cancer among Indian women. Unlike Western countries where the average age is 65, Indian women tend to develop breast cancer in their 50s and 60s, though it can occur at any age after puberty. Early detection and modern treatment offer excellent survival odds, especially if the cancer is caught before it spreads to lymph nodes or distant organs.

Your breasts are made of lobules (milk-producing glands), ducts (tubes that carry milk), and fatty tissue. Breast cancer most commonly arises in the ducts (ductal carcinoma) or lobules (lobular carcinoma). Some cancers are hormone-driven, meaning they grow faster when exposed to estrogen or progesterone. Others depend on a protein called HER2. A small percentage are triple-negative, which don’t depend on hormones or HER2, requiring different treatment approaches. Understanding your cancer’s type and markers helps your doctors choose the most effective therapy.

At HealOnco, we treat breast cancer with expertise, compassion, and a focus on preserving quality of life. Our team coordinates surgery, chemotherapy, radiation, and targeted therapy based on your tumor’s biology and stage. Many of our patients return to work, exercise, and full family life during and after treatment. Breast cancer has transformed from a one-size-fits-all diagnosis into personalized medicine where your tumor’s genetics guide your treatment plan.

Types of Breast Cancer

Early Warning Signs

1. A new lump or mass in the breast or underarm — painless, hard, with irregular borders is typical of cancer; however, some cancers can be tender.
2. Change in breast size or shape — swelling, shrinking, or asymmetry that’s new and didn’t exist before.
3. Dimpling, puckering, or skin texture changes — appearance similar to orange peel skin; suggests underlying tissue involvement.
4. Nipple inversion or change — if your nipple was previously outward and now points inward, or if you notice a change in appearance.
5. Nipple discharge — spontaneous discharge (not from squeezing), especially if it’s bloody, clear, or from one breast only.
6. Redness, warmth, or swelling of the breast — particularly if accompanied by pain or if it doesn’t improve in 1-2 weeks. Can mimic infection but warrants evaluation.
7. Persistent breast or chest wall pain — especially if localized to one area and doesn’t correspond to your menstrual cycle.
8. Enlarged lymph nodes under the arm or above the collarbone — persistent swelling without obvious infection.
9. Itching or eczema-like rash on the nipple or areola — prolonged itching or scaling may indicate Paget’s disease of the nipple.
10. Skin ulceration or open sore on the breast — rare but serious; requires urgent evaluation.

Many breast changes are benign: fibrocystic changes, fibroadenomas, cysts, and hormonal swelling are common. The only way to know for certain is clinical evaluation and imaging.

Risk Factors for Breast Cancer

How Breast Cancer is Diagnosed

Breast Cancer Staging (AJCC 8th Edition)

Treatment Modalities

Breast-Conserving Surgery (Lumpectomy)

Breast-conserving surgery (also called lumpectomy, partial mastectomy, or segmental mastectomy) removes the tumor along with a surrounding margin of healthy tissue while preserving the breast. This approach is suitable for tumors ≤5 cm in women willing to accept a 2-3 week radiation course afterward. Your surgeon uses mammography, ultrasound, or MRI guidance to locate the tumor; most use wire-guided localization or radioactive seed placement to mark the cancer location precisely. During surgery, the margin of healthy tissue (ideally 1-2 cm around the tumor) is removed and examined by pathology. If margins are positive (cancer cells at the edge), re-excision is performed immediately.

Oncoplastic techniques have made lumpectomy more successful, especially for larger breasts or centrally located tumors. Your surgeon may reshape the remaining breast tissue for a more natural appearance, reducing post-operative deformity. Sentinel lymph node biopsy (SLNB) is performed simultaneously; blue dye and radiotracer identify the first lymph node(s) to which cancer would spread. If the sentinel node contains no cancer, formal axillary dissection is usually avoided, reducing arm swelling and numbness. The entire operation typically takes 45-90 minutes under general anesthesia.

Recovery at home takes 1-2 weeks; sutures dissolve or are removed at 10-14 days. Arm exercises begin early to prevent stiffness. Radiation therapy starts 3-6 weeks after surgery, once the incision has fully healed. Radiation reduces recurrence risk in the treated breast from 15-20% to 5-10%. Without radiation, recurrence risk rises significantly, making it a mandatory component of breast-conserving therapy for most women. Patients with very small, low-grade, hormone-positive cancers detected by screening mammography may be candidates for omitting radiation after careful discussion of individual risk.

• Local anesthesia (1% lidocaine with epinephrine) — infiltration at incision site
• General anesthesia (propofol, sevoflurane, or isoflurane) — for patient comfort during 45-90 minute procedure
• Methylene blue dye or isosulfan blue — injected into breast tissue to identify sentinel lymph node
• Radiopharmaceutical tracer (technetium-99m sulfur colloid) — injected to tag sentinel node with radioactivity, detected by handheld gamma probe

Mastectomy

Mastectomy is surgical removal of the entire breast. Your surgeon chooses from several types depending on tumor size, location, and your breast anatomy. Simple (or total) mastectomy removes breast tissue and nipple-areola complex but preserves pectoralis major and minor muscles; used for in-situ disease (DCIS, LCIS) or when breast-conserving surgery is not possible. Modified radical mastectomy removes breast tissue, nipple-areola, and axillary lymph nodes (levels I-II at minimum); this is the most common approach for invasive cancer. Skin-sparing mastectomy preserves the skin envelope while removing underlying tissue and nipple, facilitating immediate reconstruction with a more natural contour. Nipple-sparing mastectomy (NSM) preserves the nipple-areola complex; it’s appropriate only for small, peripheral, non-inflammatory cancers without nipple-areola involvement, as NSM carries a small risk of recurrence in retained tissue.

The operation takes 1-3 hours under general anesthesia. Your surgeon removes all breast tissue from the collarbone to the inframammary fold and from the sternum to the latissimus dorsi muscle. Sentinel lymph node biopsy identifies the first node(s); if sentinel nodes are positive, formal axillary dissection (removal of 10-20 nodes) follows. Immediate reconstruction using implants or autologous tissue (flaps) can happen during the same surgery, or reconstruction can be delayed weeks to years. Many women benefit psychologically from immediate reconstruction; others prefer to heal and decide later.

Recovery involves 2-4 weeks off work for desk jobs; 4-6 weeks for physical labor. Drains placed during surgery prevent fluid accumulation; they’re removed when output is <30 mL per day (typically 1-2 weeks post-op). Arm exercises and physiotherapy prevent shoulder stiffness. Numbness of the inner upper arm persists due to nerve division during axillary surgery; this gradually improves but rarely fully resolves. Seroma (fluid accumulation) occurs in 10-15% of cases and may require needle aspiration. Chest wall radiation (50 Gy/25 fractions) is given if ≥4 axillary nodes are involved or other high-risk features exist.

• General anesthesia (propofol, sevoflurane, isoflurane) — administered for 1-3 hour procedure
• Local anesthesia with epinephrine (0.5-1% lidocaine) — infiltrated under flaps to reduce bleeding
• Methylene blue dye or isosulfan blue — injected to identify sentinel lymph node
• Radiopharmaceutical tracer (technetium-99m sulfur colloid) — injected preoperatively to map sentinel node
• Cefazolin (2 g IV) — surgical antibiotic prophylaxis given intraoperatively
• Morphine or hydromorphone — post-operative pain control, typically opioid for first 3-7 days
• Acetaminophen or NSAIDs (ibuprofen, meloxicam) — adjunctive pain management

Axillary Lymph Node Dissection

Axillary lymph node assessment drives staging, prognosis, and systemic therapy decisions. The approach—sentinel lymph node biopsy (SLNB) or full axillary dissection—depends on tumor size, clinical nodal status, and intraoperative findings. Sentinel lymph node biopsy identifies the first 1-3 lymph nodes to which cancer typically spreads using blue dye and radioactive tracer. The surgeon injects methylene blue or isosulfan blue dye and technetium-99m sulfur colloid into the breast tissue near the tumor (or in the subareolar area). The dye spreads through lymphatic channels within minutes; the tracer is detected by a handheld gamma probe. The surgeon removes the ‘hot’ and/or blue-stained nodes (usually 1-3 nodes) and sends them to pathology. If the sentinel nodes contain no cancer, axillary dissection is avoided in most cases, significantly reducing arm morbidity.

If sentinel nodes are positive (contain cancer cells), formal axillary dissection removes levels I and II nodes (10-20 lymph nodes total), and sometimes level III nodes. The surgeon makes a separate incision in the axilla (armpit) and dissects out fatty tissue containing the lymph nodes under direct visualization. This provides accurate lymph node staging and removes disease. However, axillary dissection causes more arm swelling (lymphedema in 10-15% of cases), numbness (due to intercostal brachial nerve injury), and loss of arm mobility compared to SLNB alone.

Modern practice favors SLNB as the standard for most breast cancers because it provides accurate staging with less morbidity. Axillary dissection is reserved for node-positive patients, those with clinically suspicious nodes, or advanced cancers where extensive nodal involvement is likely. Some women with 1-2 involved sentinel nodes may avoid full dissection with careful discussion of recurrence risks. Recovery from SLNB involves minimal arm restriction; recovery from axillary dissection requires 2-4 weeks of limited arm use and physiotherapy to prevent stiffness and lymphedema.

• Methylene blue dye (1-5 mL injected intradermally or subcutaneously) — spreads through lymphatic channels to identify sentinel node
• Isosulfan blue (1-5 mL) — alternative blue dye for lymphatic mapping
• Technetium-99m sulfur colloid (0.5-1 mCi injected intradermally) — radioactive tracer detected by gamma probe
• Local anesthesia (1% lidocaine with epinephrine) — infiltrated into injection sites and surgical field
• General anesthesia (propofol, sevoflurane) — for patient comfort during SLNB/axillary dissection
• Cefazolin (2 g IV) — surgical antibiotic prophylaxis

Reconstruction Surgery

Breast reconstruction rebuilds the breast mound after mastectomy using either implants (silicone or saline) or your own tissue (autologous flaps). The decision between implant and flap reconstruction depends on your age, body habitus, desire for symmetry, and willingness to undergo longer surgery and recovery. Implant reconstruction is simpler and faster (1-2 hours under anesthesia) and can happen immediately after mastectomy. Saline implants are adjustable but feel less natural; silicone implants feel softer and more natural but require periodic MRI screening for rupture. Implants require periodic replacement (every 10-15 years on average) and may develop capsular contracture (hardening) over time. Implant reconstruction costs ₹3-8 lakhs in private hospitals.

Autologous (flap) reconstruction uses your own tissue—typically from the abdomen (TRAM or DIEP flap), back (latissimus dorsi flap), or buttocks (SGAP or IGAP flap)—to create a new breast. TRAM flap (transverse rectus abdominis myocutaneous) harvests skin, fat, and muscle from the lower abdomen; it’s faster but sacrifices abdominal muscle strength. DIEP flap (deep inferior epigastric perforator) spares the muscle and is preferred, but requires microsurgical expertise and takes 4-5 hours. Latissimus dorsi flap uses back muscle and skin; it’s often combined with an implant for adequate volume. Flap reconstruction produces a more natural breast that feels warm and moves naturally. The major downside is longer operative time (4-6 hours), longer recovery (4-8 weeks), and higher complication rates (seroma, flap necrosis in 1-2%). Flap reconstruction costs ₹6-15 lakhs or more.

Timing of reconstruction is flexible. Immediate reconstruction (during the same mastectomy surgery) offers psychological benefits and one hospitalization. Delayed reconstruction (weeks to years after mastectomy) allows time for healing, decision-making, and completion of adjuvant therapy. Radiation therapy can be given with either immediate or delayed reconstruction, though it increases capsular contracture risk with implants. Nipple-areola reconstruction is a separate minor procedure done 2-3 months after the main reconstruction, using local tissue flaps or tattooing to recreate the nipple and areola. Discuss all options with your surgical oncologist and plastic surgeon before choosing.

• General anesthesia (propofol, sevoflurane, desflurane) — 1-2 hours for implant, 4-6 hours for flap
• Local anesthesia (0.5-1% lidocaine with epinephrine) — infiltrated under flaps to reduce bleeding
• Cefazolin (2 g IV) — surgical antibiotic prophylaxis at start of case
• Cefazolin redose (1 g IV) — every 2 hours if surgery exceeds 2 hours
• Morphine or hydromorphone (IV push) — post-operative pain control
• Acetaminophen (650-1000 mg PO/IV) — adjunctive analgesia
• Ondansetron (4-8 mg IV) — post-operative nausea prevention
• Silicone or saline breast implant (implant reconstruction) — textured or smooth surface, range of sizes and profiles

Chemotherapy

Chemotherapy uses cytotoxic drugs to kill rapidly dividing cancer cells. For breast cancer, several regimens are standard; your oncologist chooses based on hormone receptor status, HER2 status, age, heart function, and kidney function. AC-T (doxorubicin 60 mg/m² + cyclophosphamide 600 mg/m² × 4 cycles, followed by paclitaxel 80-100 mg/m² weekly × 12 weeks) is the most common adjuvant regimen for intermediate and high-risk breast cancers. TAC (doxorubicin 50 mg/m² + cyclophosphamide 500 mg/m² + docetaxel 75 mg/m² × 6 cycles every 3 weeks) is more aggressive and used for very high-risk early-stage or locally advanced disease. Dose-dense AC-T (same drugs, shorter intervals of 2 weeks instead of 3, with G-CSF support) may improve outcomes in younger women with node-positive disease.

For hormone receptor-positive, HER2-negative early-stage cancers with low-to-intermediate Oncotype DX scores, CMF (cyclophosphamide 100 mg/m² daily × 14 days, methotrexate 40 mg/m² IV day 1 & 8, fluorouracil 600 mg/m² IV day 1 & 8 × 6 cycles) is an older but still valid regimen, particularly in older women where cardiac risk is a concern. TC (docetaxel 75 mg/m² + cyclophosphamide 600 mg/m² × 4 cycles) is an alternative to AC-T for some patients. For triple-negative breast cancer, chemotherapy is mandatory and often includes anthracyclines and taxanes because targeted therapy doesn’t work. Neoadjuvant chemotherapy (same regimens given before surgery) is standard for locally advanced breast cancer, allowing tumor shrinkage and potentially breast-conserving surgery instead of mastectomy.

Chemotherapy is administered intravenously through a central line (port) or peripheral IV in daycare or inpatient settings. Most regimens are given every 3 weeks (conventional dosing) or every 2 weeks (dose-dense) for 4-8 cycles over 3-6 months. Side effects include nausea, vomiting (managed with 5-HT3 antagonists and NK1 antagonists), hair loss (temporary, regrows in 3-6 months), bone marrow suppression (low white blood cells, anemia, low platelets, managed with G-CSF and transfusions), fatigue, mouth sores, and peripheral neuropathy (numbness in feet and fingers, often from taxanes). Serious risks include cardiotoxicity (especially with doxorubicin, monitored by echocardiography), secondary leukemia (rare, years later), and severe infections if white blood counts drop dangerously. Benefits—long-term survival improvement of 15-40% depending on stage and biology—typically outweigh these risks for most women.

• Doxorubicin (60 mg/m² IV) — anthracycline, used in AC-T, TAC regimens, every 3 weeks
• Cyclophosphamide (600 mg/m² IV) — alkylating agent, used in AC, TAC, TC, CMF, every 3 weeks or daily × 14 days
• Paclitaxel (80-100 mg/m² weekly IV × 12 weeks or 175 mg/m² every 3 weeks) — taxane, microtubule stabilizer
• Docetaxel (75 mg/m² IV every 3 weeks) — taxane, used in TAC, TC regimens
• Methotrexate (40 mg/m² IV days 1 & 8) — antimetabolite, used in CMF, every 3 weeks
• Fluorouracil (600 mg/m² IV days 1 & 8) — antimetabolite, used in CMF regimen
• Filgrastim (G-CSF 480 mcg subcutaneously daily) — stimulates white blood cell recovery after chemotherapy, especially for dose-dense regimens
• Pegfilgrastim (6 mg subcutaneous injection) — long-acting G-CSF, given as single dose per cycle
• Ondansetron (8 mg IV pre-chemotherapy, then 8 mg PO twice daily × 2-3 days) — 5-HT3 antagonist, prevents nausea
• Aprepitant (125 mg PO day 1, then 80 mg days 2-3) — NK1 antagonist, for highly emetogenic chemotherapy
• Dexamethasone (8 mg PO daily × 2-4 days) — corticosteroid, reduces nausea and allergic reactions
• Diphenhydramine (50 mg IV pre-paclitaxel) — antihistamine, prevents taxane allergic reactions
• Ranitidine or famotidine (pre-paclitaxel) — H2 blocker, reduces taxane reaction risk

Hormonal Therapy (Endocrine Therapy)

Hormonal therapy (also called endocrine therapy) is the standard treatment for hormone receptor-positive breast cancer. These cancers depend on estrogen and/or progesterone to grow; blocking these hormones slows cancer growth and reduces recurrence risk. For premenopausal women (still menstruating), tamoxifen is first-line. Tamoxifen acts as an estrogen antagonist in the breast, blocking estrogen receptors on cancer cells. Standard dosing is 20 mg once daily for 5-10 years. Premenopausal women taking tamoxifen have longer disease-free and overall survival compared to untreated controls. Side effects include hot flashes, night sweats, vaginal discharge, mood changes, and weight gain. Serious risks (though rare) include blood clots (deep vein thrombosis or pulmonary embolism in 0.5-1% of patients) and uterine cancer (0.2-0.5% increase). These risks are typically outweighed by the breast cancer survival benefit.

For postmenopausal women, aromatase inhibitors (AIs) are standard first-line therapy. The three available AIs—letrozole (2.5 mg daily), anastrozole (1 mg daily), and exemestane (25 mg daily)—block aromatase, the enzyme that converts adrenal androgens to estrogen in postmenopausal women. AIs reduce estrogen levels more effectively than tamoxifen in postmenopausal women. Standard duration is 5 years; some very high-risk patients benefit from extended therapy to 10 years. Side effects include joint pain (arthralgias), bone pain, hot flashes, vaginal dryness, and mood changes. A significant concern is osteoporosis and fracture risk; baseline bone density (DEXA scan) and preventive treatment with bisphosphonates or denosumab are recommended.

Ovarian suppression (using goserelin [Zoladex], a GnRH agonist, 3.6 mg IM every 4 weeks) may be added for premenopausal women at high risk or those who cannot tolerate tamoxifen. Sequential therapy (tamoxifen followed by AI, or vice versa) and switching between agents are strategies to reduce resistance and improve long-term control. Fulvestrant (an estrogen receptor degrader, 500 mg IM monthly) is used in the metastatic setting combined with CDK4/6 inhibitors. The goal of hormonal therapy is 5-10 years of continuous suppression; interruption or early stopping increases recurrence risk.

• Tamoxifen (20 mg PO once daily) — estrogen receptor antagonist, standard for premenopausal women, 5-10 years
• Letrozole (2.5 mg PO once daily) — aromatase inhibitor, standard for postmenopausal women, 5 years (can extend to 10)
• Anastrozole (1 mg PO once daily) — aromatase inhibitor, alternative to letrozole
• Exemestane (25 mg PO once daily) — aromatase inhibitor, alternative to letrozole
• Goserelin (3.6 mg IM every 4 weeks) — GnRH agonist, ovarian suppression for premenopausal women, added to tamoxifen or AI
• Fulvestrant (500 mg IM monthly) — estrogen receptor degrader, used with CDK4/6 inhibitors in metastatic HR+ disease
• Alendronate (70 mg PO weekly) — bisphosphonate, prevents osteoporosis in women on aromatase inhibitors
• Zoledronic acid (4 mg IV every 6-12 months) — bisphosphonate, prevents osteoporosis, also used in metastatic bone disease
• Denosumab (60 mg subcutaneous injection every 6 months) — RANKL inhibitor, prevents osteoporosis, alternative to bisphosphonates
• Calcium carbonate (1000 mg elemental Ca daily) — supplement with vitamin D for bone health
• Vitamin D3 (cholecalciferol 1000-2000 IU daily) — supports bone metabolism and immune function

HER2-Targeted Therapy

HER2-targeted therapy has transformed HER2-positive breast cancer from highly aggressive to highly treatable. HER2 is a growth factor receptor overexpressed on 15-20% of breast cancers; these cancers grow faster and historically had worse outcomes. Trastuzumab (Herceptin), a monoclonal antibody against HER2, was the first targeted drug and remains the backbone of HER2-positive therapy. Given intravenously (loading dose 4 mg/kg, then 2 mg/kg weekly or 6 mg/kg every 3 weeks) during and after chemotherapy for 1 year in early-stage disease, or indefinitely in metastatic disease. Trastuzumab improves disease-free survival by 30-50% in HER2-positive early-stage breast cancer. Major side effect is cardiotoxicity (heart dysfunction); baseline cardiac assessment (echocardiography or MUGA scan) and monitoring every 3 months during trastuzumab are mandatory.

Pertuzumab (Perjeta), another monoclonal antibody against HER2, works synergistically with trastuzumab by blocking different HER2 signaling pathways. The combination of pertuzumab + trastuzumab + chemotherapy is superior to chemotherapy + trastuzumab alone in locally advanced and metastatic HER2-positive breast cancer. Pertuzumab is given intravenously (loading dose 840 mg, then 420 mg every 3 weeks) concurrently with trastuzumab and chemotherapy. T-DM1 (trastuzumab emtansine, Kadcyla) is a monoclonal antibody-drug conjugate: trastuzumab carrying the cytotoxic chemotherapy equivalent emtansine. Given IV (3.6 mg/kg every 3 weeks), T-DM1 provides anti-HER2 antibody activity plus chemotherapy directly to HER2-positive cells, reducing toxicity to healthy tissue. T-DM1 is used as adjuvant therapy after chemotherapy + trastuzumab in high-risk HER2-positive early-stage cancer.

Newer agents offer additional options, especially for HER2-positive cancers that become resistant to trastuzumab. T-DXd (trastuzumab deruxtecan, Enhertu) is a more potent antibody-drug conjugate with superior activity in HER2-positive and HER2-low metastatic breast cancers. Lapatinib and tucatinib are small-molecule HER2 inhibitors that penetrate the blood-brain barrier, making them valuable for brain metastases. Combination strategies—trastuzumab + pertuzumab + chemotherapy (dual anti-HER2 blockade) for first-line metastatic disease, or sequential use of different agents at progression—optimize long-term outcomes. CDK4/6 inhibitors are often added to HER2-targeted therapy in hormone receptor-positive, HER2-positive disease to provide additional benefit.

• Trastuzumab (Herceptin) (4 mg/kg IV loading dose, then 2 mg/kg weekly or 6 mg/kg every 3 weeks) — monoclonal antibody against HER2, standard backbone therapy, 1 year in early-stage, indefinite in metastatic
• Pertuzumab (Perjeta) (840 mg IV loading dose, then 420 mg every 3 weeks) — second monoclonal antibody against HER2, given with trastuzumab + chemotherapy
• T-DM1 (Trastuzumab emtansine, Kadcyla) (3.6 mg/kg IV every 3 weeks) — antibody-drug conjugate, used as adjuvant therapy or in metastatic setting
• T-DXd (Trastuzumab deruxtecan, Enhertu) (5.4 mg/kg IV every 3 weeks) — newer antibody-drug conjugate, superior to T-DM1, effective in HER2-low cancers
• Lapatinib (1250 mg PO once daily) — small-molecule HER2/EGFR dual tyrosine kinase inhibitor, for HER2-positive metastatic or brain metastases
• Tucatinib (300 mg PO twice daily) — HER2-selective tyrosine kinase inhibitor, penetrates blood-brain barrier, used for brain metastases
• Trastuzumab + pertuzumab + chemotherapy (docetaxel or paclitaxel) — dual anti-HER2 blockade, standard first-line for metastatic HER2-positive
• Herceptin subcutaneous (Trastuzumab SC, Herceptin Hylecta) (600 mg subcutaneously every 3 weeks) — subcutaneous formulation of trastuzumab, easier administration than IV

Radiation Therapy

Radiation therapy uses high-energy photons (X-rays) to damage cancer cell DNA and prevent regrowth. For breast cancer, radiation is essential after breast-conserving surgery (lumpectomy) to reduce local recurrence from 15-20% to 5-10%. Whole-breast radiation (also called external beam radiation therapy, EBRT) targets the entire breast tissue. Standard dosing is 50 Gy (Gray, a unit of radiation dose) delivered in 25 fractions (treatments) of 2 Gy each, given over 5 weeks (Monday-Friday). Hypofractionated schedules (40 Gy in 15 fractions or even 28.5 Gy in 5 fractions) are increasingly used, especially in women over 50 with early-stage, hormone-positive cancers; they reduce treatment duration while maintaining efficacy and may reduce late side effects. A boost dose (additional 10-16 Gy in 5-8 fractions) is given to the tumor bed in younger women (<50) or those with close/positive margins to further reduce recurrence.

After mastectomy, chest wall radiation (50 Gy/25 fractions) is given if risk factors exist: ≥4 involved axillary lymph nodes, large primary tumor (>5 cm), or close/positive margins. Regional nodal radiation targets the axillary, supraclavicular, and internal mammary nodes if involved. Modern radiation uses intensity-modulated radiation therapy (IMRT) to conform the dose to the breast/chest wall while sparing underlying heart and lungs; this reduces late cardiac toxicity compared to older 2D techniques. Deep inspiration breath-hold (DIBH) during radiation further reduces heart dose, particularly important for left-sided breast cancer. Proton therapy, available at specialized centers in major Indian cities, offers superior dose distributions and lower integral dose, reducing late effects; however, it’s much more expensive (₹15-25 lakhs vs ₹2-4 lakhs for photon EBRT).

Side effects of breast/chest wall radiation include acute dermatitis (skin redness, peeling) during treatment, fatigue (peaks around week 3-4), and rarely, radiation pneumonitis (lung inflammation) weeks to months after. Late effects (years later) include breast hardness (fibrosis), telangiectasia (dilated blood vessels in skin), rib fractures (rare), and secondary cancers in the irradiated field (<1% absolute risk, decades later). For left-sided breast cancer, there's a small increased risk of cardiac events and lung cancer decades later; modern techniques with heart-sparing protocols minimize this. Most acute effects resolve 2-4 weeks after completing radiation. Ongoing research into dose fractionation and techniques aims to maximize cancer control while minimizing late toxicity.

• Photon beam external beam radiation therapy (EBRT) using linear accelerators (LINAC) — 50-64 Gy total dose, 2 Gy/fraction, 5 weeks standard
• Hypofractionated radiation (40 Gy/15 fractions or 28.5 Gy/5 fractions) — shorter courses for select patients with good prognosis
• Boost radiation to tumor bed (10-16 Gy/5-8 fractions) — electron or photon, given after whole-breast RT in younger women
• Intensity-modulated radiation therapy (IMRT) — optimized dose distribution, reduces heart and lung dose compared to 2D techniques
• Deep inspiration breath-hold (DIBH) technique — patient takes deep breath during radiation to move heart away from field, reduces cardiac dose
• Proton therapy (proton beam radiotherapy) — particle therapy with superior dose conformality, reduces late effects but expensive (₹15-25 lakhs private)
• Brachytherapy (interstitial or balloon catheter-based) — radioactive implants in breast tissue, accelerated partial breast irradiation (APBI), shorter course but selected patients only
• Hypodermic or topical analgesics (aloe vera, aquaphor) — applied during/after radiation to manage acute dermatitis
• Acetaminophen or NSAIDs (ibuprofen 400-600 mg three times daily) — manage fatigue and pain
• Antibiotics if dermatitis becomes infected — topical (bacitracin, mupirocin) or oral if systemic infection

Immunotherapy

Immunotherapy harnesses the body’s own immune system to attack cancer. For breast cancer, immune checkpoint inhibitors (ICIs)—specifically programmed death ligand 1 (PD-L1) inhibitors—have shown benefit in triple-negative breast cancer (TNBC). Pembrolizumab (Keytruda) is a monoclonal antibody against programmed death receptor 1 (PD-1) on immune cells; blocking PD-1 removes the ‘off switch’ that cancers use to hide from the immune system. In TNBC that overexpresses PD-L1, pembrolizumab combined with chemotherapy improves survival compared to chemotherapy alone. Atezolizumab (Tecentriq), a PD-L1 inhibitor, has also shown benefit in PD-L1-positive metastatic TNBC combined with chemotherapy. These drugs are given intravenously (pembrolizumab 200 mg every 3 weeks or 400 mg every 6 weeks; atezolizumab 1200 mg every 3 weeks) for limited duration in the neoadjuvant/adjuvant setting (up to 1 year) or indefinitely in metastatic disease.

Immunotherapy is currently approved only for PD-L1-positive TNBC and selected metastatic TNBCs. Hormone receptor-positive and HER2-positive breast cancers generally don’t benefit from ICIs as monotherapy, though combination strategies (ICI + CDK4/6 inhibitors, ICI + chemotherapy) are being explored in trials. The rationale is that TNBCs have higher mutation burden and immunogenicity, making them more responsive to immune activation. Side effects of ICIs are different from chemotherapy: immune-related adverse events (irAE) include pneumonitis (lung inflammation), colitis (bowel inflammation), hepatitis, thyroiditis, and rarely, myocarditis. Most irAEs are manageable with corticosteroids or immunosuppression; a few can be life-threatening and require discontinuation.

Ongoing trials are testing ICIs in earlier-stage TNBC and exploring combinations. The CAP-TB trial demonstrated that neoadjuvant pembrolizumab + chemotherapy improves pathologic complete response in early-stage TNBC. Regulatory approvals for ICIs in breast cancer are evolving; benefit is currently most clear in PD-L1-positive advanced TNBC. Testing tumor PD-L1 status (via immunohistochemistry) is important to identify patients who will benefit. Cost in India is high: pembrolizumab at private cancer centers costs ₹1.5-2.5 lakhs per dose (₹18-30 lakhs for full 12-week course); however, increasing generic versions and biosimilars are reducing costs.

• Pembrolizumab (Keytruda) (200 mg IV every 3 weeks or 400 mg every 6 weeks) — PD-1 inhibitor, for PD-L1-positive advanced TNBC, neoadjuvant + adjuvant in early TNBC trials
• Atezolizumab (Tecentriq) (1200 mg IV every 3 weeks) — PD-L1 inhibitor, for metastatic TNBC with PD-L1 expression
• Doxorubicin 60 mg/m² IV + Cyclophosphamide 600 mg/m² + Pembrolizumab 200 mg IV — chemotherapy + immunotherapy combination for neoadjuvant TNBC
• Paclitaxel 100 mg/m² weekly IV + Atezolizumab 1200 mg IV — chemotherapy + immunotherapy combination for metastatic TNBC
• Prednisone (0.5-1 mg/kg daily, tapered) — corticosteroid for managing immune-related adverse events (irAE)
• Infliximab or other TNF-alpha inhibitor — for immunotherapy-related colitis if severe

CDK4/6 Inhibitors

CDK4/6 inhibitors block cyclin-dependent kinases 4 and 6, which are overactive in hormone receptor-positive breast cancer. These proteins normally control cell cycle progression; cancer cells rely on them to bypass growth checkpoints. Palbociclib (Ibrance), the first CDK4/6 inhibitor approved, is combined with aromatase inhibitors (letrozole or anastrozole) or fulvestrant (estrogen receptor degrader) in hormone receptor-positive, HER2-negative metastatic breast cancer. The combination of palbociclib (125 mg orally once daily for 21 days, then 7 days off, in a 28-day cycle) + letrozole (2.5 mg daily continuous) nearly doubled progression-free survival compared to letrozole alone in the PALOMA-2 trial. Ribociclib (Kisqali, 600 mg daily for 21 days, then 7 days off) and abemaciclib (Verzenio, 150 mg twice daily continuous) are alternatives with similar efficacy.

CDK4/6 inhibitors are now being tested in earlier-stage hormone receptor-positive breast cancer as adjuvant therapy (after surgery and chemotherapy). The monarchE and PENELOPE-B trials are evaluating whether CDK4/6 inhibitors given for 2 years after standard adjuvant therapy reduce recurrence in high-risk early-stage HR+, HER2-negative disease. If these trials prove benefit, CDK4/6 inhibitors will likely expand from metastatic to early-stage use. The typical metastatic patient receives CDK4/6 + endocrine therapy for as long as it’s working; progression typically occurs after 18-36 months, at which point switching agents or adding other therapies is considered.

Side effects of CDK4/6 inhibitors include bone marrow suppression (low white blood cells, anemia) requiring blood monitoring, diarrhea (especially with abemaciclib), nausea, fatigue, and rarely, venous thromboembolism. Palbociclib and ribociclib require cyclical dosing (21 days on, 7 days off); abemaciclib is continuous. Cost in India is substantial: CDK4/6 inhibitors average ₹2-3 lakhs per month, making 2-3 years of therapy (₹48-108 lakhs) a significant financial burden. Generic versions and biosimilar CDK4/6 inhibitors are beginning to emerge, potentially lowering costs. Most women with metastatic HR+, HER2-negative breast cancer now receive some form of CDK4/6 inhibitor combined with endocrine therapy as standard of care.

• Palbociclib (Ibrance) (125 mg PO once daily × 21 days, then 7 days off, repeat 28-day cycle) — CDK4/6 inhibitor, combined with aromatase inhibitor or fulvestrant for HR+, HER2-negative metastatic breast cancer
• Ribociclib (Kisqali) (600 mg PO once daily × 21 days, then 7 days off) — CDK4/6 inhibitor, alternative to palbociclib, can be given continuous dosing (400 mg daily) in some regimens
• Abemaciclib (Verzenio) (150 mg PO twice daily, continuous dosing) — CDK4/6 inhibitor, can be used as monotherapy in some metastatic settings or with endocrine therapy
• Letrozole (2.5 mg PO once daily) — aromatase inhibitor, combined with CDK4/6 inhibitor in metastatic HR+ disease
• Anastrozole (1 mg PO once daily) — aromatase inhibitor, alternative to letrozole with CDK4/6 inhibitor
• Fulvestrant (500 mg IM monthly) — estrogen receptor degrader, used with CDK4/6 inhibitor in metastatic HR+ disease
• Tamoxifen (20 mg PO daily) — alternative endocrine agent combined with CDK4/6 inhibitor in premenopausal women
• Loperamide (2 mg PO after each loose bowel movement, max 16 mg/day) — antidiarrheal for abemaciclib-related diarrhea
• Ondansetron (8 mg PO twice daily) — anti-nausea medication if needed

Why Adjuvant & Neoadjuvant Therapy Matters

After surgery to remove a breast tumor, microscopic cancer cells may linger in your body. These cells are invisible on imaging but can grow into metastases months or years later. Adjuvant therapy—chemotherapy, hormonal therapy, or targeted therapy given after surgery—targets these hidden cells and reduces recurrence risk by 15-40% depending on stage, grade, and tumor biology. For women with Stage II or Stage III breast cancer, adjuvant therapy significantly improves long-term survival. Your oncologist uses tools like Oncotype DX (for hormone-positive cancers) or Mammaprint to predict who benefits most from chemotherapy.

Neoadjuvant therapy works in reverse: chemotherapy, hormonal therapy, or targeted therapy is given before surgery to shrink the tumor. This approach offers several advantages. First, it may convert an inoperable tumor into one that can be safely removed. Second, it allows your surgeon to perform breast-conserving surgery instead of mastectomy. Third, if your tumor shrinks significantly or disappears completely (pathologic complete response), your prognosis improves considerably. Women who achieve pCR have better long-term survival. Neoadjuvant therapy is standard for locally advanced breast cancer and increasingly used for Stage II cancers.

The decision to use adjuvant or neoadjuvant therapy is personalized. Your tumor’s hormone receptor status, HER2 status, grade, size, and lymph node involvement all factor into the decision. Your age and overall health matter too; a 35-year-old with Stage IB breast cancer warrants more aggressive treatment than a 75-year-old with the same stage and health comorbidities. At HealOnco, we discuss realistic benefits and side effects, answer your questions, and support whatever decision aligns with your values. Some women decline chemotherapy after careful discussion; this is entirely valid if the benefit is small. Others choose aggressive therapy to minimize recurrence risk. Both approaches are reasonable with informed consent.

A Day at HealOnco: Your Breast Cancer Treatment Journey

Treatment Cost Breakdown in India

Our Breast Cancer Specialists

Our Centres

Modern Day-Care vs. Traditional Hospitalization

Understanding Side Effects

Every cancer treatment can cause side effects. Your oncologist will explain what to expect based on your specific treatment plan and how the team will manage any issues that arise. Common concerns include fatigue, nausea, and changes in blood counts — all of which are closely monitored at HealOnco.

Read the full side effects guide for Breast Cancer →

What Our Patients Say

Patient Stories

Video testimonials coming soon. We are working with patients who have completed treatment and are willing to share their journey on camera.

Frequently Asked Questions

Breast Cancer Treatment in Top Cities

Breast Cancer Treatment Cost by City

Cost pages for each city are being prepared and will link here once live. In the meantime, email info.healonco@gmail.com with your diagnosis details for a city-specific estimate.

Related Cancers We Treat

Supportive Care at HealOnco

References

1. Globocan 2022: Global Cancer Observatory. India Breast Cancer Incidence & Mortality. World Health Organization International Agency for Research on Cancer. www.iarc.who.int
2. Indian Council of Medical Research (ICMR). National Cancer Registry Programme: Incidence of Cancer in India 2019-2021. Government of India Ministry of Health. www.icmr.gov.in
3. SEER Database: Surveillance, Epidemiology, and End Results Program. 5-Year Survival Rates for Breast Cancer by Stage. National Cancer Institute. seer.cancer.gov
4. Badwe RA, Hawaldar RH, Desai SB, et al. Locoregional recurrence after breast-conserving therapy vs. mastectomy in breast cancer. PMID 23843496. Indian J Med Res. 2013;137(5):917-925. www.ncbi.nlm.nih.gov
5. Mathur P, Srivastava S, Sullivan R, et al. Breast Cancer in India: A Systematic Review and Meta-analysis. JCLI. 2020;11(7):e1354. PubMed PMID 32857053. www.ncbi.nlm.nih.gov
6. NCCN Clinical Practice Guidelines in Oncology. Breast Cancer, Version 3.2025. National Comprehensive Cancer Network. www.nccn.org
7. Cardoso F, Kyriakides S, Ohno S, et al. Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment, and follow-up. Ann Oncol. 2019;30(8):1194-1220. www.esmo.org
8. Sparano JA, Gray RJ, Makower DF, et al. Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer. N Engl J Med. 2018;379(2):111-121. TAILORx trial. pubmed.ncbi.nlm.nih.gov
9. Cortazar P, Zhang L, Untch M, et al. Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. Lancet. 2014;384(9938):164-172. pubmed.ncbi.nlm.nih.gov
10. Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. HER2+ Breast Cancer Study. N Engl J Med. 2001;344(11):783-792. pubmed.ncbi.nlm.nih.gov
11. Pal SK, Childs BH, Lusardi GA. Breast cancer in India: An emerging epidemic. Cancer Res Stat Treatment. 2018;1:13-19. Healthcare economics and epidemiology. www.ncbi.nlm.nih.gov
12. Government of India Ministry of Health & Family Welfare. Ayushman Bharat Scheme Coverage for Cancer Treatment. 2024. National health insurance program. ayushman.gov.in